학술논문
Myopic Laser-Assisted Subepithelial Keratectomy (LASEK) outcomes using three different excimer laser platforms: a retrospective observational study
Document Type
Report
Author
Source
BMC Ophthalmology. October 15, 2019, Vol. 19 Issue 1
Subject
Language
English
ISSN
1471-2415
Abstract
Author(s): Isabel Rodríguez-Pérez[sup.1,2] , Juan Gros-Otero[sup.3] , Miguel A. Teus[sup.1,4] , Rafael Caéones[sup.4] and Montserrat García-González[sup.1,3] Background Both laser in situ keratomileusis (LASIK) and surface ablation (SA) have been proven [...]
Background To compare the visual and refractive outcomes after myopic LASEK using three different excimer lasers and standardized surgical and mitomycin C (MMC) application protocols. Methods In this retrospective, observational cohort study, we examined 122 eyes treated with Allegretto, 135 eyes treated with Esiris and 137 eyes treated with Technolas excimer lasers. All eyes were treated under the same surgical protocol, and a standardized MMC dosage was used. The three groups were refraction-matched, and both visual and refractive outcomes were evaluated at 1 and 7 days and 1 and 3 months after surgery. Results At 3 months postsurgery, Allegretto provided significantly better outcomes than Esiris and Technolas in terms of postoperative uncorrected distance visual acuity (UDVA) (1.11 [+ or -] 0.2 vs 1.01 [+ or -] 0.2 vs 0.98 [+ or -] 0.2) (P = 0.0001), corrected distance visual acuity (CDVA) (1.13 [+ or -] 0.2 vs 1.10 [+ or -] 0.1 vs 1.04 [+ or -] 0.2) (P = 0.0001), residual sphere (- 0.01 [+ or -] 0.2 vs + 0.29 [+ or -] 0.7 vs + 0.27 [+ or -] 0.6) (P = 0.0001), and efficacy index (0.99 [+ or -] 0.2 vs 0.90 [+ or -] 0.2 vs 0.91 [+ or -] 0.2) (P = 0.0004). Conclusions We found slightly better visual and refractive outcomes in the Allegretto group at 3 months post-op after LASEK with MMC to correct myopia. Keywords: Myopia, LASEK, Excimer laser, Mitomycin C
Background To compare the visual and refractive outcomes after myopic LASEK using three different excimer lasers and standardized surgical and mitomycin C (MMC) application protocols. Methods In this retrospective, observational cohort study, we examined 122 eyes treated with Allegretto, 135 eyes treated with Esiris and 137 eyes treated with Technolas excimer lasers. All eyes were treated under the same surgical protocol, and a standardized MMC dosage was used. The three groups were refraction-matched, and both visual and refractive outcomes were evaluated at 1 and 7 days and 1 and 3 months after surgery. Results At 3 months postsurgery, Allegretto provided significantly better outcomes than Esiris and Technolas in terms of postoperative uncorrected distance visual acuity (UDVA) (1.11 [+ or -] 0.2 vs 1.01 [+ or -] 0.2 vs 0.98 [+ or -] 0.2) (P = 0.0001), corrected distance visual acuity (CDVA) (1.13 [+ or -] 0.2 vs 1.10 [+ or -] 0.1 vs 1.04 [+ or -] 0.2) (P = 0.0001), residual sphere (- 0.01 [+ or -] 0.2 vs + 0.29 [+ or -] 0.7 vs + 0.27 [+ or -] 0.6) (P = 0.0001), and efficacy index (0.99 [+ or -] 0.2 vs 0.90 [+ or -] 0.2 vs 0.91 [+ or -] 0.2) (P = 0.0004). Conclusions We found slightly better visual and refractive outcomes in the Allegretto group at 3 months post-op after LASEK with MMC to correct myopia. Keywords: Myopia, LASEK, Excimer laser, Mitomycin C